TY - JOUR
T1 - Vasopressin in chronic kidney disease
T2 - An elephant in the room
AU - Torres, Vicente E.
PY - 2009/11
Y1 - 2009/11
N2 - Perico et al. report that a dual arginine vasopressin (AVP) V 2 and V 1a receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V 2 and V 1a receptors and potential usefulness of V 2 and V 1a receptor antagonists remain ill defined.
AB - Perico et al. report that a dual arginine vasopressin (AVP) V 2 and V 1a receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V 2 and V 1a receptors and potential usefulness of V 2 and V 1a receptor antagonists remain ill defined.
UR - http://www.scopus.com/inward/record.url?scp=70350070609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350070609&partnerID=8YFLogxK
U2 - 10.1038/ki.2009.325
DO - 10.1038/ki.2009.325
M3 - Comment/debate
C2 - 19829311
AN - SCOPUS:70350070609
SN - 0085-2538
VL - 76
SP - 925
EP - 928
JO - Kidney international
JF - Kidney international
IS - 9
ER -